HER2 and topoisomerase IIα: Possible predictors of response to neoadjuvant chemotherapy for breast cancer patients

Chinese Medical Journal

Volumn 121, Issue 20, 2008, Pages 1965-1968

  Zhu, Li ^a   Li, Ya Fen ^a   Chen, Wei Guo ^a   He, Jian Rong ^a   Peng, Chen Hong ^a   Zhu, Zheng Gang ^a   Li, Hong Wei ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Breast neoplasms; DNA topoisomerase II alpha; Genes; HER2; Neoadjuvant chemotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MASTECTOMY; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PREDICTION; PROTEIN EXPRESSION; TREATMENT OUTCOME; BREAST TUMOR; CHEMISTRY; GENETICS; MIDDLE AGED; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 58749108111     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200810020-00003     Document Type: Article

References (21)

1. Wolff AC, Davidson NE. Primary systemic therapy in operable breast cancer. J Clin Oncol 2000; 18: 1558-1569.
2. Fisher B, Mamounas E. Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer. J Clin Oncol 1995; 13: 537-540.
3. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
4. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 1986; 46: 2578-2581.
5. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. Clinical course of breast cancer patients with complete pathologic primary - tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17: 460-469.
6. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-440.
7. Keith WN, Douglas F, Wishart GC, McCallum HM, George WD, Kaye SB, et al. Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20. Eur J Cancer 1993; 29A: 1469-1475.
8. Murphy DS, McHardy P, Coutts J, Mallon EA, George WD, Kaye SB, et al. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ. Int J Cancer 1995; 64: 18-26.
9. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, et al. erbB-2 and response to doxorubicin in patients with axillary lymph nodepositive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998; 90: 1361-1370.
10. Paik S, Bryant J, Tan-Chiu E, Yothers Q Park C, Wickerham DL, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Proto col B-15. J Natl Cancer Inst 2000; 92: 1991-1998.
11. Moliterni A, Menard S, Valagussa P, Biganzoli E, Boracchi P, Balsari A, et al. HER2 overexpression and doxorubicin in-the adjuvant chemotherapy of resectable breast rancer. J Clin Oncol 2003; 21: 458-462.
12. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 2001; 19: 2334-2356.
13. Monfardini S, Brunne K, Crowther D. Evaluation of the cancer patient and the response to treatment. In: UICC-manual of adult and pediatric medical oncology. Berlin: Springer; 1987: 2238.
14. Sandri MI, Hochbauser D, Ayton P, Camplejohn RC, Whitehouse R, Turley H, et at. Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. Br J Cancer 1996; 73: 1518-1524.
15. Durbecq V, Desmedt C, Paesmans M, Cardoso F, Di Leo A, Mano M, et al. Correlation between topoisomerase IIalpha gene amplification and protein expression in Her-2 amplified breast cancer. Int J Oncol 2004; 25: 1473-1479.
16. Coon JS, Marcus E, Gupta-Burt S, Seeling S, Jacobson K, Chen S, et al. Amplification and overexpression of topoisomerase IIa predict response to anthracyclinebased therapy in locally advanced breast cancer. Clin Cancer Res 2002; 8: 1061-1067.
17. Di Leo A, Gancberg D, Larsimont D, Tanuer M, Jarvinen T, Rousa G, et al. HER-2 amplification and topoisomerase IIa gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002; 8: 1107-1116.
18. Di Leo A, Larsimont D, Gancberg D, Jarvinen T, Beauduin M, Vindevoghel A, et al. HER-2 and topo-isomerase IIa as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001; 12: 1081-1089.
19. Withoff S, Keith WN, Knol AJ, Coutts JC, Hoare SF, Mulder NH, et al. Selection of a subpopulation with fewer DNA topoisomerase IIa gene copies in a doxorubicin-resistant cell panel. Br J Cancer 1996; 74: 502-507.
20. Jarvinen TAH, Tanner M, Rantanen V, Barlund M, Borg A, Gremman S, et al. Amplification and deletion of topoisomerase IIa associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-847.
21. Park K, Kim J, Lim S, Han S. Topoisomerase II-a (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer 2003; 39: 631-634.